# Arthritis, Psoriatic FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/arthritis-psoriatic

> 8 upcoming FDA catalysts in arthritis, Psoriatic: sonelokimab (MLTX) on January 2027 (primary completion); ICOTYDE (icotrokinra, JNJ) on Feb to May 2027 (topline data readout); ICOTYDE (icotrokinra, JNJ) on February 2027 (primary completion); sonelokimab (MLTX) on Q2 2027 (topline data readout); and 4 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 25, 2026 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | completed | "NCT06878404 (A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06878404)) |
| May 28, 2026 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | completed | "NCT06641076 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-28 (ACTUAL); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641076)) |
| January 2027 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT06641089 (Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641089)) |
| Feb to May 2027 | [ICOTYDE (icotrokinra) topline data readout](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | scheduled | "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807424)) |
| February 2027 | [ICOTYDE (icotrokinra) primary completion](https://sec-api.dev/pdufa/icotrokinra) | JNJ | Arthritis, Psoriatic | scheduled | "NCT06807424 (A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-10 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807424)) |
| Q2 2027 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "◦IZAR-1: Expected to announce Week 52 topline results in Q2 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821586/000182158626000013/moonlake-pressreleasexq320.htm)) |
| Jun to Sep 2027 | [JNJ-88545223 topline data readout](https://sec-api.dev/pdufa/jnj-88545223) | JNJ | Arthritis, Psoriatic | scheduled | "NCT07321873 (A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321873)) |
| June 2027 | [JNJ-88545223 primary completion](https://sec-api.dev/pdufa/jnj-88545223) | JNJ | Arthritis, Psoriatic | scheduled | "NCT07321873 (A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-28 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07321873)) |
| Feb to May 2028 | [Sonelokimab topline data readout](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223138)) |
| February 2028 | [Sonelokimab primary completion](https://sec-api.dev/pdufa/sonelokimab) | MLTX | Arthritis, Psoriatic | scheduled | "NCT07223138 (A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2028-02-04 (ESTIMATED); Lead Sponsor MoonLake Immunotherapeutics AG." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07223138)) |

## Drugs

- [ICOTYDE (icotrokinra)](https://sec-api.dev/pdufa/icotrokinra) (JNJ)
- [Sonelokimab](https://sec-api.dev/pdufa/sonelokimab) (MLTX)
- [JNJ-88545223](https://sec-api.dev/pdufa/jnj-88545223) (JNJ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/arthritis-psoriatic.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Arthritis, Psoriatic FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/arthritis-psoriatic

```bibtex
@misc{secapidev_indications_arthritis_psoriatic_20261116,
  title        = {Arthritis, Psoriatic FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/arthritis-psoriatic}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_arthritis_psoriatic_20261116","title":"Arthritis, Psoriatic FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/arthritis-psoriatic","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
